Prestigious Annual Prize Is Worth $35,000

Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug Administration (FDA) for MagicTouch PTA (Percutaneous Transluminal Angioplasty), its Sirolimus drug-coated balloon (DCB) catheter, for the treatment of Peripheral Artery Disease (PAD) in Below-the-Knee (BTK). The first 'Breakthrough Device Designation' received by Concept Medical Inc. was on 30th April 2019 for its MagicTouch SCB, for the treatment of Coronary Artery Disease (CAD) in patients with in-stent restenosis.

Changes will foster research and innovation in the organization's next chapter

This report studies the global market size of Injectable Bone Graft, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Injectable Bone Graft production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.

Benoit Bruneau is selected to lead the Gladstone Institute of Cardiovascular Disease

Small nonprofit run by parent volunteers seeking to make a big impact and save their children

Experts on Medical Marijuana Will Discuss Potential Health Benefits, Risks and Current Trends

Lotus Clinical Research Announces the Addition of Lee Simon, MD as Principal Advisor, Osteoarthritis Research and Allan Green, MD, PhD, JD as Medical Imaging and Research Advisor

Neil Singla, Chief Executive Officer of Lotus Clinical Research, Chaired the fourth annual American Pain Society Conference on Analgesic Trials (APS-CAT)

Asia Pacific biomedical refrigerators and freezers market is expected to register 5.4% CAGR over the forecast period.

Pediatric segment of multiparameter patient monitoring market will register 4%+ CAGR from 2019 to 2025

Study by Gladstone scientists finds blood protein destroys memory storage sites in the brain and may lead to new treatments

Robert Dworkin, Ph.D. Joins Lotus Clinical Research as Director, Chronic Pain Research to lead Lotus' chronic pain research programs